ASKLEPIOS continues focus on Group’s further development in financial year 2026

In the first quarter of 2026, ASKLEPIOS is continuing on its path of stable development. During the first three months of the financial year, the ASKLEPIOS Group’s healthcare facilities treated a total of 1,043,748 patients, an increase of 9.3% YoY (previous year: 954,522 patients). In the inpatient segment, case numbers increased by 5.0% to reach 207,054 patients (previous year: 197,129 patients). The dynamic trend in outpatient cases also continued, as seen in the 10.5% increase to a total of 836,694 patients treated in this segment (previous year: 757,393 patients).

Consolidated revenue at the end of the first quarter of 2026 stood at EUR 1,636.4 million, up 5.0% over the previous year’s level (previous year: EUR 1,558.4 million). This resulted in consolidated earnings after tax (EAT) of EUR 32.6 million with a margin of 2.3% (previous year: EUR 22.5 million, 1.4%).

Despite the continuing improvements in the ASKLEPIOS Group’s results, the external environment remains challenging. The highly unpredictable regulatory, legislative as well as (geo-)political environment is giving rise to persistently negative economic impacts such as inflation and cost pressures.

The current hospital reforms and ongoing regulatory meddling are having a significant influence on the further trend. Under these framework conditions, the financial impacts for hospitals are growing significantly. Particularly the implementation of the Hospital Reform Adjustment Act (Krankenhausreformanpassungsgesetz, KHAG) and the end to temporary relief measures under the Act to Stabilise the Finances of the Statutory Health Insurance Funds (SHI)s (GKV-Finanzstabilisierungsgesetz (GKV-FinStG)) are confronting hospitals with additional challenges when it comes to their financing, remuneration structures and investment capacities.

CEO Joachim Gemmel: “As the current hospital reforms are significantly encroaching on hospitals’ existing care and financing structures, it is not possible at this time to make any reliable predictions on what the impacts will be in the long term. In addition, growing regulatory interference is exacerbating the situation of many hospitals considerably. Unless adjustments to the reforms are made soon, and in the absence of reliable financing structures, there is a serious risk of detrimental structural impacts on medical care and a deterioration of the German hospital landscape in the long term.”

CEO Marco Walker: “Despite the demanding regulatory, policy and economic environment, we are making targeted investments in the further development of our sites and processes while combining a high quality of medical care with steadfast efforts to digitalise our processes. In this way we are creating the basis for modern and efficient healthcare delivery while strengthening our Group’s performance on a sustainable basis.”